Crossmark

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-021-05190-z

Published Online: 2021-04-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vergis, Nikhil https://orcid.org/0000-0002-4157-6757
Phillips, Rachel

Cornelius, Victoria

Katsarou, Alexia

Youngstein, Taryn

Cook, Lucy

Willicombe, Michelle

Pilay, Clio

Shturova, Tina

Almonte, Melanie

Charania, Asad

Turner, Richard

Kon, Onn Min

Cooke, Graham

Thursz, Mark

Cherlin, Svetlana

Wason, James

Milojkovic, Dragana

Innes, Andew J.

Cooper, Nichola
Funding

Funding for this research was provided by:

Novartis Pharmaceuticals UK Limited

Rigel Pharmaceuticals Ltd

NIHR Imperial Biomedical Research Centre
License Information

Text and Data Mining valid from 2021-04-12

Version of Record valid from 2021-04-12
More Information

Article History

Received: 11 March 2021

Accepted: 13 March 2021

First Online: 12 April 2021

Declarations

:

: The study was approved by the London-Surrey Borders Health Research Ethics Committee 20/HRA/2618, 24<sup>th</sup> September 2020We certify that this trial has received ethical approval from the appropriate ethical committee as described above. We will obtain consent from participants to participate in the study or from their personal or professional representative if the patient lacks capacity but might still benefit from inclusion in the study.

: Not applicable

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below